Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks


Allegro has progressed its R&D program for its lead drug candidate, Luminate®, as a novel treatment option for DME, Wet AMD, VMT and other vitreoretinal indications.

Luminate® has been shown in clinical trials to reduce the frequency of injections from every 4-8 weeks to quarterly or trimester for patients with DME or Wet AMD, keeping the disease and vision under better control. Additionally, Luminate® has been shown to be an effective treatment option for DME and Wet AMD patients that either do not respond or have less than an excellent response to anti-VEGF therapy.

While anti-VEGF agents target the signaling for the creation of new blood vessels, Luminate® interferes with the construction of new blood vessels by working from a unique mechanism of action that targets integrin receptor sites implicated in new blood vessel construction and proliferation. In addition to this anti-angiogenic mechanism of action, Luminate®’s second mechanism of action, vitreolysis, induces posterior vitreous detachment and vitreous liquefaction which are beneficial for treating vitreoretinal disorders.

The most prevalent vitreoretinal conditions being studied by Allegro to be treated with Luminate® include:

Diabetic Retinopathy (DR) & Diabetic Macular Edema (DME)

  • 10.2 million people in the U.S. over age 40 have been diagnosed with diabetes, of which 4.1 million have some form of DR
  • The prevalence of DME among US diabetics approaches 30 percent in adults who have had diabetes for 20 years or more

Wet Age-Related Macular Degeneration (Wet AMD)

  • Approximately 15 million Americans are affected with AMD
  • Projecting 30 million Americans will be affected by 2020
  • 10% of AMD patients will develop Wet AMD

Vitreomacular Traction (VMT)

More than 250,000 Americans are affected with VMT

  • VMT is divided into two patient categories: those with macular holes and those with VMT

The incidence of VMT is reported as high as 84% for patients with macular hole, 100% for patients with vitreomacular traction syndrome, and 56% in idiopathic epimacular membrane (Koerner F, Garweg J. [Diseases of the vitreo-macular interface]. Klin Monbl Augenheilkd. 1999;214(5):305-310.)

Symptoms for VMT most commonly include:

  • Metamorphopsia
  • Decreased Visual Acuity
  • Central Visual Field Defect